Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
about
DNA damage-mediated induction of a chemoresistant nicheThe SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be minedThe Role of the Transcriptional Regulation of Stromal Cells in Chronic InflammationNovel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and developmentSOCS, inflammation, and cancerTherapeutic strategies for the clinical blockade of IL-6/gp130 signalingMolecular pathogenesis of hepatic adenomas and its implications for surgical managementβ-Catenin Signaling and Roles in Liver Homeostasis, Injury, and TumorigenesisDangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancerInflammation- and stress-related signaling pathways in hepatocarcinogenesisInflammation and skeletal metastasisGenetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivoA cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesisStat3 is a candidate epigenetic biomarker of perinatal Bisphenol A exposure associated with murine hepatic tumors with implications for human healthSTATs in cancer inflammation and immunity: a leading role for STAT3Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expressionFocal nodular hyperplasia with major sinusoidal dilatation: a misleading entity.Intracellular signaling prevents effective blockade of oncogenic gp130 mutants by neutralizing antibodies.IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis.Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activationGrowth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.Next-generation genomic profiling of hepatocellular adenomas: a new era of individualized patient care.Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapyStat3: linking inflammation to epithelial cancer - more than a "gut" feeling?Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damageRole of Wnt/β-catenin signaling in liver metabolism and cancerRapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome dataInhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma.Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function.HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines.Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells.Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytesSTAT3 activation in monocytes accelerates liver cancer progression.Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse.gp130 at the nexus of inflammation, autoimmunity, and cancer.LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease.A gp130-Src-YAP module links inflammation to epithelial regeneration.HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytesMiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3.
P2860
Q24616267-E40ED992-FCDC-4F78-BC86-F602F55DD361Q26748848-B3A48FCC-2C27-4A5C-BBC0-52A86CBF0B32Q26778930-7D49C49B-640B-4084-982A-233225913B4AQ26851211-45D5D19E-DD66-42C6-BDE3-C0DF00E19028Q26991808-959873A3-ACE8-4BA6-891F-7689D0FE3C3DQ27002391-BB2FD826-FFC7-4968-BEB0-675710DF37FEQ27027370-93D395E5-5CA3-4AE2-A291-EAE5316EDBABQ28087660-990C009B-E235-42D7-B1B7-31B65F6E1D06Q28267996-2BB4C35D-20C8-4E9F-8E73-CE9EC0CB2EBBQ28387669-3CA870B4-C32D-4C1A-BC8F-EDAD67CEFBEFQ28396089-C0479FC7-5093-4843-A17F-06D207E5D39BQ28472494-FFF8762C-4A08-4867-9623-52BC369FF34FQ28818626-430D2CE2-2057-4B10-9A8E-A5379C8B118DQ28834275-99AFDB11-2F6D-4B29-A1F3-4D4730D8B9E5Q29547203-D1745D31-F955-4F7C-9C79-4594BBADF54BQ29615766-0707BB52-240C-4EB5-90B5-8D91085AB310Q30460181-4BA8F9AA-C747-45C7-9C23-94138DD2735DQ33557104-7D797F53-09A5-462A-A2DA-77691B54EF7BQ33561833-BD000857-206A-4BF4-AD5F-97FF885D9D00Q33737707-266895CA-4E6E-4019-A88C-478DC36C5900Q33779633-01875055-6A68-4A5A-A9CA-90D991AD0256Q33833379-1AC3DA8E-705A-437A-9AEB-532390CA95BCQ33866426-C89D0670-5E48-4A6B-AA7B-08C72DA5D559Q33921803-5AE9983A-F899-4660-8D4A-69482E8722D4Q33930343-5665E33C-85E4-4E80-A1A8-4EB03275EE68Q33940403-55C30AEF-E5B8-4E63-8D8F-3129F990B88FQ33951424-B6DD8F48-BFCE-4CE2-B5CC-7069E0770951Q33959754-F20DE552-202E-4B77-8196-6627B77387BFQ33970149-FD9FF7CB-EDCF-4F35-ACD0-E5928866E488Q33979918-7FA9FC6A-F68C-4ED6-AF13-65C75DC8F31BQ34040991-566D4D2E-DBB9-49CB-82B2-1CDE1A820F7DQ34056571-33CDF59F-A105-48E4-9819-F277E8525EA9Q34078669-B0B87D59-6EAF-4C29-8A3E-7EC274A3545EQ34089708-DCE4F695-E23F-4223-AFF7-DD09AB07CA79Q34185231-3E1F6D42-3DCE-4469-87CC-955253EAB2AEQ34378756-EFC4F25E-1690-47D3-BC90-B591843FF6D5Q34434347-09671BB0-9A76-4FA0-A284-712E9768ACA0Q34465259-400EFB06-0F7A-4DD0-A695-EECDC864F571Q34651638-73745D9D-1121-4B91-B733-667A6BBA0922Q34934907-8874AB49-395E-4C02-B4B3-D5C5E755868F
P2860
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
@en
Frequent in-frame somatic dele ...... matory hepatocellular tumours.
@nl
type
label
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
@en
Frequent in-frame somatic dele ...... matory hepatocellular tumours.
@nl
prefLabel
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
@en
Frequent in-frame somatic dele ...... matory hepatocellular tumours.
@nl
P2093
P2860
P50
P356
P1433
P1476
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
@en
P2093
Charles Balabaud
Gabrielle Couchy
Karine Poussin
Mohamed Amessou
Tina Izard
P2860
P2888
P304
P356
10.1038/NATURE07475
P407
P577
2008-11-19T00:00:00Z
P5875
P6179
1032605043